Milestone Scientific Crescita futura
Criteri Future verificati 1/6
Si prevede che Milestone Scientific aumenterà gli utili e i ricavi rispettivamente del 25.6% e 13.4% all'anno, mentre si prevede che l'EPS crescerà del 25.7% all'anno.
Informazioni chiave
25.6%
Tasso di crescita degli utili
25.68%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 16.1% |
| Tasso di crescita dei ricavi | 13.4% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 19 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 27
MLSS: Medical Adoption And New Capital Raise Will Support Future Upside
Analysts have adjusted their price target on Milestone Scientific to $1.00, supported by updated assumptions that include a slightly lower discount rate, revised revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Reaffirmed earnings guidance for 2026, with expected revenue of US$9.8 million to US$10.2 million, tied to commercial adoption in both dental and medical segments (Corporate Guidance).Aggiornamento della narrazione • May 04
MLSS: Expanded Share Authorization And Private Placement Will Support Future Upside
Milestone Scientific's analyst price target has been adjusted slightly, with analysts pointing to small refinements in the discount rate, long term profit margin assumptions and future P/E expectations as key drivers of the updated valuation. What's in the News Entered a securities purchase agreement for a private placement of 7,962,963 units at $0.27 per unit, for gross proceeds of about $2.15m.Aggiornamento della narrazione • Apr 18
MLSS: Expanded Share Authorization Will Support Future Upside As Guidance And PE Strengthen
Analysts have adjusted their price target on Milestone Scientific to reflect a modest change in the assumed discount rate and profit margin. They are keeping fair value at $1.00 while updating their future P/E outlook to 72.06x based on the latest inputs.Aggiornamento della narrazione • Apr 03
MLSS: Expanded Share Authorization Will Support Future Upside As Revenue Guidance Strengthens
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on slightly different revenue growth expectations, profit margin assumptions and a revised forward P/E profile, while keeping the fair value estimate broadly aligned with prior levels in dollar terms. What's in the News Management issued earnings guidance for the year ending December 31, 2026, with expected total revenue in a range of US$9.8 million to US$10.2 million, citing broadening commercial adoption in both dental and medical segments (company guidance).Aggiornamento della narrazione • Mar 19
MLSS: Expanded Share Authorization Will Support Future Upside From Current Levels
Analysts have modestly adjusted their price target on Milestone Scientific to reflect updated views on discount rates, profit margins, and future P/E expectations, while keeping the fair value estimate unchanged at $1.00 per share. What's in the News The company filed a Certificate of Amendment to its Restated Certificate of Incorporation in Delaware on March 10, 2026, increasing authorized common stock from 100,000,000 to 125,000,000 (Key Developments).Aggiornamento della narrazione • Mar 05
MLSS: Shares Will Likely Rise As Expanded Authorization Supports Undervaluation
Analysts have modestly raised their price target on Milestone Scientific to $1.00. The change reflects slightly higher assumed discount rates and price-to-earnings expectations, along with a marginally lower profit margin outlook in their updated models.Aggiornamento della narrazione • Feb 18
MLSS: Shares Will Likely Rise As Share Authorization Supports Undervaluation
Analysts have nudged their price target on Milestone Scientific slightly higher to $1.00, reflecting small tweaks to the discount rate, profit margin assumptions, and future P/E inputs in their models. What's in the News Shareholders ratified the appointment of CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditors for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (Key Developments).Aggiornamento della narrazione • Feb 03
MLSS: Shares Will Likely Rise As Increased Share Authorization Supports Undervaluation
Analysts have adjusted their price target on Milestone Scientific to align with updated assumptions around discount rates, profit margins, and future P/E expectations. This has led to a modest shift in the projected valuation range expressed in US$ terms.Aggiornamento della narrazione • Jan 20
MLSS: Shares Will Likely Rise As Auditor Approval Supports Undervaluation
Analysts have slightly lifted their price target on Milestone Scientific to around US$1.00, citing small tweaks to their discount rate, profit margin outlook, and a projected future P/E of about 71x as the main drivers of the updated view. What's in the News Shareholders approved CBIZCPA P.C. as Milestone Scientific Inc.'s independent auditor for the fiscal year ending December 31, 2025, at the AGM held on December 18, 2025 (AGM filing).Aggiornamento della narrazione • Jan 06
MLSS: Shares Will Likely Rise As Listing Plan Supports Undervaluation
Analysts have made a modest adjustment to their price target on Milestone Scientific, keeping fair value anchored at US$1.00 while fine tuning assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News At the December 18, 2025 AGM, shareholders approved an amendment to Milestone Scientific's Restated Certificate of Incorporation to increase authorized common shares from 100,000,000 to 125,000,000 (AGM filing).Aggiornamento della narrazione • Dec 19
MLSS: Shares Will Likely Rise As Listing Compliance Risks Ease
Analysts have modestly increased their price target on Milestone Scientific to reflect a slightly lower perceived risk in future cash flows, despite trimming long term profit margin assumptions and applying a higher forward earnings multiple. What's in the News Proposed amendment to the Restated Certificate of Incorporation to increase authorized common shares from 100 million to 125 million, expanding potential equity financing capacity (company filing).Aggiornamento della narrazione • Dec 04
MLSS: Shares Will Likely Rebound As NYSE Compliance Plan Progresses
Analysts have trimmed their price target on Milestone Scientific from 1.13 dollars to 1.00 dollars, citing slightly slower expected revenue growth and a modestly lower valuation multiple. This is partially offset by stable profit margin assumptions and a marginally reduced discount rate.Aggiornamento della narrazione • Nov 20
MLSS: Shares Will Face Key NYSE American Compliance Decision by 2027
Analysts have revised their price target for Milestone Scientific downward from $1.63 to $1.13. They cite lower projected revenue growth and a higher discount rate as key factors influencing their updated outlook.Aggiornamento della narrazione • Aug 19
CompuFlo Epidural System Will Unlock New Global Opportunities
The downward revision in Milestone Scientific’s price target reflects materially lower revenue growth expectations, leading to a drop in projected fair value from $2.12 to $1.62. What's in the News Eric C.
Nuova narrazione • Apr 07
CompuFlo Epidural System Will Unlock New Global Opportunities
Strategic partnerships and regulatory approvals are expanding market access for the CompuFlo Epidural System, potentially driving significant revenue growth.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2027 | 11 | -3 | N/A | 0 | 2 |
| 12/31/2026 | 10 | -3 | N/A | -1 | 2 |
| 3/31/2026 | 9 | -5 | -2 | -2 | N/A |
| 12/31/2025 | 9 | -6 | -3 | -3 | N/A |
| 9/30/2025 | 9 | -7 | -4 | -4 | N/A |
| 6/30/2025 | 9 | -7 | -5 | -5 | N/A |
| 3/31/2025 | 9 | -5 | -3 | -3 | N/A |
| 12/31/2024 | 9 | -5 | -3 | -3 | N/A |
| 9/30/2024 | 9 | -5 | -3 | -3 | N/A |
| 6/30/2024 | 8 | -5 | -3 | -3 | N/A |
| 3/31/2024 | 9 | -7 | -5 | -5 | N/A |
| 12/31/2023 | 10 | -7 | -5 | -5 | N/A |
| 9/30/2023 | 10 | -7 | -5 | -5 | N/A |
| 6/30/2023 | 10 | -7 | -5 | -5 | N/A |
| 3/31/2023 | 9 | -8 | -7 | -7 | N/A |
| 12/31/2022 | 9 | -9 | -6 | -6 | N/A |
| 9/30/2022 | 9 | -8 | -5 | -5 | N/A |
| 6/30/2022 | 9 | -8 | -6 | -6 | N/A |
| 3/31/2022 | 10 | -8 | -5 | -5 | N/A |
| 12/31/2021 | 10 | -7 | -4 | -4 | N/A |
| 9/30/2021 | 10 | -7 | -4 | -4 | N/A |
| 6/30/2021 | 9 | -6 | -5 | -5 | N/A |
| 3/31/2021 | 7 | -7 | -7 | -7 | N/A |
| 12/31/2020 | 5 | -7 | -7 | -7 | N/A |
| 9/30/2020 | 6 | -9 | -7 | -7 | N/A |
| 6/30/2020 | 6 | -10 | -5 | -5 | N/A |
| 3/31/2020 | 8 | -8 | -3 | -3 | N/A |
| 12/31/2019 | 8 | -8 | N/A | -2 | N/A |
| 9/30/2019 | 10 | -4 | N/A | -1 | N/A |
| 6/30/2019 | 10 | -6 | N/A | -1 | N/A |
| 3/31/2019 | 10 | -6 | N/A | -1 | N/A |
| 12/31/2018 | 10 | -7 | N/A | -2 | N/A |
| 9/30/2018 | 8 | -9 | N/A | -2 | N/A |
| 6/30/2018 | 9 | -6 | N/A | -2 | N/A |
| 3/31/2018 | 9 | -7 | N/A | -1 | N/A |
| 12/31/2017 | 11 | -5 | N/A | -1 | N/A |
| 9/30/2017 | 11 | -5 | N/A | -3 | N/A |
| 6/30/2017 | 11 | -6 | N/A | -3 | N/A |
| 3/31/2017 | 11 | -6 | N/A | -5 | N/A |
| 12/31/2016 | 10 | -6 | N/A | -5 | N/A |
| 9/30/2016 | 11 | -6 | N/A | -3 | N/A |
| 6/30/2016 | 11 | -5 | N/A | -4 | N/A |
| 3/31/2016 | 10 | -6 | N/A | -4 | N/A |
| 12/31/2015 | 9 | -5 | N/A | -3 | N/A |
| 9/30/2015 | 10 | -5 | N/A | -3 | N/A |
| 6/30/2015 | 10 | -4 | N/A | -2 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che MLSS rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che MLSS rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che MLSS rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di MLSS ( 13.4% all'anno) crescerà più rapidamente del mercato US ( 11.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di MLSS ( 13.4% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di MLSS è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/09 10:21 |
| Prezzo dell'azione a fine giornata | 2026/06/09 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Milestone Scientific Inc. è coperta da 3 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Bruce Jackson | Benchmark Company |
| Anthony Vendetti | Maxim Group |
| James Terwilliger | Northland Capital Markets |